Barclays PLC Orchard Therapeutics PLC Transaction History

Barclays PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.16 - $2.23 $1,532 - $2,945	-1,321 Reduced 39.78%	2,000 $3,000
Q3 2021 Nov 09, 2021	BUY	$2.24 - $4.29 $2,676 - $5,126	1,195 Added 56.21%	3,321 $8,000
Q2 2021 Aug 13, 2021	SELL	$4.39 - $7.23 $649 - $1,070	-148 Reduced 6.51%	2,126 $10,000
Q1 2021 May 13, 2021	BUY	$4.39 - $9.08 $232 - $481	53 Added 2.39%	2,274 $17,000
Q4 2020 Feb 11, 2021	BUY	$3.86 - $5.07 $386 - $507	100 Added 4.71%	2,221 $10,000
Q3 2020 Nov 12, 2020	BUY	$4.11 - $6.45 $8,220 - $12,900	2,000 Added 1652.89%	2,121 $8,000
Q2 2020 Aug 12, 2020	SELL	$5.75 - $11.99 $11,247 - $23,452	-1,956 Reduced 94.17%	121 $1,000
Q1 2020 May 13, 2020	SELL	$5.65 - $15.71 $1,039 - $2,890	-184 Reduced 8.14%	2,077 $16,000
Q4 2019 Feb 10, 2020	SELL	$10.15 - $15.58 $133,634 - $205,126	-13,166 Reduced 85.34%	2,261 $32,000
Q3 2019 Nov 14, 2019	BUY	$11.88 - $16.72 $110,008 - $154,827	9,260 Added 150.15%	15,427 $183,000
Q2 2019 Aug 14, 2019	BUY	$13.2 - $20.63 $79,794 - $124,708	6,045 Added 4954.92%	6,167 $87,000
Q1 2019 May 15, 2019	BUY	$12.01 - $19.49 $264 - $428	22 Added 22.0%	122 $2,000
Q4 2018 Feb 14, 2019	BUY	$12.4 - $18.7 $1,240 - $1,870	100 New	100 $2,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.